Date: 2012-10-24
Type of information: Production agreement
Compound: follistatin
Company: Royal DSM (The Netherlands) Paranta Biosciences (Australia)
Therapeutic area: Respiratory diseases - Inflammatory diseases
Type agreement: manufacturing
production
Action mechanism:
Disease: respiratory diseases, inflammatory diseases
Details: DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM has signed a biologics contract manufacturing agreement with Paranta Biosciences. The contract covers the process development and cGMP manufacture by DSM of Paranta\'s lead recombinant human protein follistatin. This project represents an agreement for DSM with an Australian customer at their Brisbane facility. Paranta Biosciences is an early stage drug development company dedicated to developing and commercializing novel biotherapeutics based on recombinant human follistatin for the treatment of respiratory diseases.
Financial terms: Financial terms were not disclosed.
Latest news:
